Would you ever offer adjuvant immunotherapy after definitive chemoradiation for esophageal cancer?

A great question – one that we really don’t have data to answer quite yet. Obviously, we do have guidance for resectable patients. CheckMate 577 was a randomized, double-blind, placebo-controlled phase 3 trial in patients with stage II or III esophageal or gastroesophageal cancer who received neoadj...